https://pharmaphorum.com/ en Thu, 21 Nov 2024 09:00:06 +0000 Wed, 20 Nov 2024 13:40:25 +0000 https://pharmaphorum.com/news/sage-wilts-huntingtons-prospect-flunks-trial Sage Therapeutics' run of bad news has continued with a failed phase 2 trial of dalzanemdor as a treatment for Huntington's disease Phil.Taylor https://pharmaphorum.com/news/sage-wilts-huntingtons-prospect-flunks-trial 2024-11-20T13:40:25+0000 Feed - News and features https://pharmaphorum.com/news/pfizer-bags-eu-okay-haemophilia-drug-hympavzi Pfizer's Hympavzi has become the first once-weekly subcutaneous treatment for people living with severe haemophilia B in the EU Phil.Taylor https://pharmaphorum.com/news/pfizer-bags-eu-okay-haemophilia-drug-hympavzi 2024-11-20T12:30:12+0000 Feed - News and features https://pharmaphorum.com/news/trump-picks-celebrity-doc-mehmet-oz-lead-medicare Donald Trump has chosen talk show host and celebrity doctor Dr Mehmet Oz to lead the Centers for Medicare and Medicaid Services Phil.Taylor https://pharmaphorum.com/news/trump-picks-celebrity-doc-mehmet-oz-lead-medicare 2024-11-20T11:09:28+0000 Feed - News and features https://pharmaphorum.com/news/nice-blames-companies-breakdown-enhertu-talks Discussions aimed at making AstraZeneca and Daiichi Sankyo's Enhertu available to breast cancer patients on the NHS have been abandoned, according to cost-effectiveness assessor NICE.The agency said the two companies had failed to put forward "a cost-effective price that would have enabled us to recommend Enhertu as value for money for the taxpayer" in the final round of negotiations. Phil.Taylor https://pharmaphorum.com/news/nice-blames-companies-breakdown-enhertu-talks 2024-11-20T09:55:28+0000 Feed - News and features https://pharmaphorum.com/news/msd-says-subcutaneous-keytruda-matches-iv-form A subcutaneous formulation of MSD's top-selling cancer immunotherapy, Keytruda, was non-inferior to the current intravenous version in a head-to-head trial, setting up regulatory filings.The new injectable version could provide a more convenient treatment option for patients and also extend the patent protection for Keytruda (pembrolizumab) – which contributed $25 billion of MSD's $60.1 billion global sales last year – which could lose market exclusivity before the end of the decade. Phil.Taylor https://pharmaphorum.com/news/msd-says-subcutaneous-keytruda-matches-iv-form 2024-11-20T08:56:48+0000 Feed - News and features